-
Head-to-Head Comparison of Treatment Strategies
Learn more about a head-to-head study that compared adding ZETIA to atorvastatin 10 mg vs titrating atorvastatin 10 mg to 20 mg. -
LDL-C Efficacy: Coadministration With Atorvastatin
See data showing that administration of ZETIA + atorvastatin provided dramatically more LDL-C reduction than the corresponding doses of atorvastatin monotherapy. -
LDL-C Efficacy of Monotherapy
Learn more about the significant LDL-C reduction provided by ZETIA. -
HDL-C Efficacy
See the effects on HDL-C when ZETIA was added to atorvastatin vs atorvastatin monotherapy. -
Mechanism of Action
An overview of how ZETIA + a statin dramatically reduces LDL-C through dual inhibition, targeting both cholesterol absorption and production.
-
LDL-C Efficacy: Coadministration With Simvastatin
See data showing that administration of ZETIA + simvastatin provided dramatically more LDL-C reduction than the corresponding doses of simvastatin monotherapy. -
Hypothetical Patient Case
Decide whether you would add ZETIA for a statin-treated patient who is >20 points from LDL-C goal on atorvastatin 10 mg. -
TG Efficacy
Review the effects on TG levels with administration of ZETIA + atorvastatin vs atorvastatin monotherapy. -
Coadministration With Fenofibrate
Review effects on LDL-C levels with administration of ZETIA + fenofibrate compared with fenofibrate monotherapy.
Important Information About ZETIA
ZETIA, administered alone or in combination with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, and Apo B in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia when diet alone is not enough.
Contraindications: hypersensitivity to any component of this medication.
Contraindications when used with a statin: active liver disease; unexplained persistent elevations of serum transaminases. Statins are contraindicated in pregnant and nursing women; refer to the statin label for details.
When using ZETIA with a statin, also follow the label recommendations for that specific statin.
The effects of ZETIA, either alone or in addition to a statin, on the risk of cardiovascular morbidity and mortality have not been established.
Selected Cautionary Information: When ZETIA was coadministered with a statin, consecutive elevations in serum transaminases (≥3 × ULN) were slightly higher (1.3%) than those of statins alone (0.4%). Liver function tests should be performed when ZETIA is added to statin therapy and according to statin recommendations.
Patients should be advised to promptly report muscle pain, tenderness, or weakness. Discontinue drug if myopathy is diagnosed or suspected.
ZETIA is not recommended in patients with moderate or severe hepatic insufficiency.
The coadministration of ZETIA with fibrates other than fenofibrate is not recommended until use in patients is studied.
Exercise caution when using ZETIA and cyclosporine concomitantly because exposure to both drugs is increased. Cyclosporine concentrations should be monitored in these patients.
ZETIA should be used in pregnant or nursing women only if the benefit outweighs the risk.
In clinical trials, the most frequent side effects for ZETIA alone vs placebo included back pain (4.1% vs 3.9%), arthralgia (3.8% vs 3.4%), and fatigue (2.2% vs 1.8%); for ZETIA + statin vs statin or placebo alone: back pain (4.3% vs 3.7% vs 3.5%), abdominal pain (3.5% vs 3.1% vs 2.3%), and fatigue (2.8% vs 1.4% vs 1.9%).
Before prescribing ZETIA, please read the Prescribing Information and Patient Product Information.
For non-US health care professionals, click here.
